Tregs, by withholding IL-2 and producing TGFβ, prevent full T-effector differentiation during the acute phase of the CD8+ T cell response, blocking differentiation into tumor-specific cytotoxic CD8+ T cells [77,94]. Here, CD8A is linked to neoplasm.